DA
ONCY

Doliver Advisors’s Oncolytics Biotech ONCY Stock Holding History

Doliver Advisors’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95K Hold
100,000
– – 0.02% 190
2026
Q1 		$84.9K Buy
+100,000
New +$99.5K 0.02% 177

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAS
Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Doliver Advisors's ONCY Position: Q2 2026 in Review

Doliver Advisors held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 100,000 shares worth $95K. The position accounts for 0.02% of the portfolio, ranked #190.

Doliver Advisors first reported a position in ONCY in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

  • Doliver Advisors held 100,000 shares of Oncolytics Biotech worth $95K as of Q2 2026.
  • Doliver Advisors left its Oncolytics Biotech share count unchanged in Q2 2026.
  • Oncolytics Biotech made up 0.02% of Doliver Advisors's portfolio in Q2 2026, its #190 holding.
  • Doliver Advisors first reported a position in Oncolytics Biotech in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.